As the health care landscape changes, the audiences for clinical trials have expanded and evolved, creating an increasingly complex environment. This paper describes the primary audiences— the Food and Drug Administration (FDA), the investment community, and the clinical community. It then details how to design and conduct clinical trials in this environment, in order to ensure regulatory approval, respond to the demands of many audiences, and guarantee the survival of biotechnology companies.
